Efsubaglutide alfa
AssetAlso called Suba
GLP-1 receptor agonist
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- GLP1R
- 3
- Indications
- 2
- Trials
- 3
- Developers
Indications
3Obesity
Phase 2, Completed, NCT06732960, clinicaltrials.gov, Nov 1, 2026
Overweight
Phase 2, Completed, NCT06732960, clinicaltrials.gov, Nov 1, 2026
Overweight and obesity
Phase 2, Active not recruiting, NCT06921486, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism1
- Owner and partners3
- Trials2
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals10
Every asset’s record: target, stage, trials and the evidence behind it.